Literature DB >> 28007549

Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus.

Isabella Marinelli1, Alies van Lier2, Hester de Melker2, Andrea Pugliese3, Michiel van Boven4.   

Abstract

Studies into the impact of vaccination against the varicella zoster virus (VZV) have increasingly focused on herpes zoster (HZ), which is believed to be increasing in vaccinated populations with decreasing infection pressure. This idea can be traced back to Hope-Simpson's hypothesis, in which a person's immune status determines the likelihood that he/she will develop HZ. Immunity decreases over time, and can be boosted by contact with a person experiencing varicella (exogenous boosting) or by a reactivation attempt of the virus (endogenous boosting). Here we use transmission models to estimate age-specific rates of reactivation and immune boosting, exogenous as well as endogenous, using zoster incidence data from the Netherlands (2002-2011, n=7026). The boosting and reactivation rates are estimated with splines, enabling these quantities to be optimally informed by the data. The analyses show that models with high levels of exogenous boosting and estimated or zero endogenous boosting, constant rate of loss of immunity, and reactivation rate increasing with age (to more than 5% per year in the elderly) give the best fit to the data. Estimates of the rates of immune boosting and reactivation are strongly correlated. This has important implications as these parameters determine the fraction of the population with waned immunity. We conclude that independent evidence on rates of immune boosting and reactivation in persons with waned immunity are needed to robustly predict the impact of varicella vaccination on the incidence of HZ.
Copyright © 2016 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Statistical inference; Transmission model; Vaccination; Varicella; Zoster

Mesh:

Year:  2016        PMID: 28007549     DOI: 10.1016/j.epidem.2016.11.001

Source DB:  PubMed          Journal:  Epidemics        ISSN: 1878-0067            Impact factor:   4.396


  8 in total

1.  Integrating measures of viral prevalence and seroprevalence: a mechanistic modelling approach to explaining cohort patterns of human papillomavirus in women in the USA.

Authors:  Andrew F Brouwer; Rafael Meza; Marisa C Eisenberg
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

2.  Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.

Authors:  Jae-Ki Choi; Sun Hee Park; Sanghyun Park; Su-Mi Choi; Si-Hyun Kim; Dong-Gun Lee; Jin-Hong Yoo; Jung-Hyun Choi; Jin Han Kang
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

3.  Changes in epidemiological characteristics and sero-prevalence against the varicella zoster virus in school-age children after the introduction of a national immunization program in Japan.

Authors:  Yosuke Yasui; Toshikatsu Mitsui; Fujiyo Arima; Keiko Uchida; Mikako Inokuchi; Mitsuaki Tokumura; Tetsuo Nakayama
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

4.  The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster.

Authors:  Luigi Marangi; Grazina Mirinaviciute; Elmira Flem; Gianpaolo Scalia Tomba; Giorgio Guzzetta; Birgitte Freiesleben de Blasio; Piero Manfredi
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

5.  Sacral (S1) herpes zoster.

Authors:  Anca Chiriac; Anca E Chiriac; Adrian Naznean; Cosmin Moldovan; Cristian Podoleanu; Simona Stolnicu
Journal:  J Pain Res       Date:  2019-05-10       Impact factor: 3.133

6.  The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.

Authors:  Christophe Sauboin; Katsiaryna Holl; Paolo Bonanni; Anne A Gershon; Bernd Benninghoff; Stephane Carryn; Margaret A Burgess; Peter Wutzler
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.667

7.  Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.

Authors:  Kevin M Bakker; Marisa C Eisenberg; Robert J Woods; Micaela E Martinez
Journal:  BMC Med       Date:  2022-10-08       Impact factor: 11.150

8.  Non-specific effects of vaccinations in high-income settings: How to address the issue?

Authors:  Alberto Donzelli; Alessandro Schivalocchi; Giulia Giudicatti
Journal:  Hum Vaccin Immunother       Date:  2018-08-27       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.